| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 18.66 | 36 |
| Intrinsic value (DCF) | 10.44 | -24 |
| Graham-Dodd Method | 27.87 | 103 |
| Graham Formula | 18.92 | 38 |
Guerbet SA (GBT.PA) is a leading French healthcare company specializing in contrast media products, medical devices, and digital solutions for diagnostic and interventional imaging. Founded in 1926 and headquartered in Villepinte, France, Guerbet operates in the medical devices sector, focusing on MRI, CT, and interventional radiology. The company's product portfolio includes well-known contrast agents like Optiray, Xenetix, and Dotarem, as well as innovative digital solutions such as Contrast&Care and icobrain, which leverage AI for neurological diagnostics. Guerbet also provides interventional radiology products like Lipiodol and Vectorio, enhancing its presence in oncology treatments. With a strong emphasis on R&D and a global footprint, Guerbet serves healthcare professionals worldwide, positioning itself as a key player in diagnostic imaging and therapeutic solutions. The company's commitment to innovation and patient care makes it a relevant and competitive force in the healthcare industry.
Guerbet SA presents a mixed investment profile. On the positive side, the company operates in the growing medical imaging and contrast media market, supported by increasing demand for diagnostic procedures. Its diversified product portfolio and focus on digital solutions (e.g., AI-driven icobrain) provide competitive differentiation. However, the company's financials show modest profitability (net income of €16.1M in the latest period) and significant debt (€392M), which could limit financial flexibility. The beta of 0.807 suggests lower volatility compared to the market, which may appeal to risk-averse investors. The dividend yield (~1.5% based on a €0.50/share payout) is modest. Investors should weigh Guerbet's niche market position against its leverage and competitive pressures from larger players like Bayer and Bracco.
Guerbet SA holds a niche but competitive position in the contrast media and medical imaging market. Its primary competitive advantage lies in its specialized product portfolio, particularly in MRI contrast agents (e.g., Dotarem) and interventional radiology solutions (e.g., Lipiodol). The company's focus on digital innovation, such as AI-powered diagnostic tools (icobrain), differentiates it from traditional contrast media providers. However, Guerbet faces intense competition from larger multinationals like Bayer (BAYN.DE) and Bracco, which have greater R&D budgets and global distribution networks. Guerbet's smaller scale limits its ability to compete on pricing, but its strong relationships with radiologists and hospitals in Europe provide a stable revenue base. The company's debt load (€392M) could constrain its ability to invest in next-generation imaging technologies, making partnerships or M&A critical for long-term growth. Its competitive positioning is further challenged by regulatory pressures and pricing constraints in healthcare systems worldwide.